Beacon Biosignals raises $27 Million Series A led by General Catalyst to scale its EEG neurobiomarker discovery platform
Summary
BOSTON, Nov. 8, 2021 /PRNewswire/ -- Beacon Biosignals, a neurotechnology company applying artificial intelligence to EEG (electroencephalography) to unlock precision medicine for any condition affecting the brain, has announced an oversubscribed $27M Series A financing led by General Catalyst and with participation from Casdin Capital. Beacon Biosignals holds one of the worlds largest clinical EEG databases and couples that data with proprietary machine learning algorithms to identify neurobiomarkers associated with patient sub-types, drug activity and therapeutic efficacy. Beacons machine learning teams develop high-performing, reliable algorithms that can replicate the adjudicated consensus interpretation of multiple trained epileptologists, as well as novel neurobiomarkers (e.g. quantitative epileptiform spike burden) that exceed human capabilities over many hours or days of recording. "It is now common knowledge that machine learning technologies will impact all corners of healthcare, but Beacon Biosignals is uniquely positioned to rapidly translate scientific and technical advances into clinical benefit for patients. With offices in San Francisco, Palo Alto, New York City, London, and Boston, the firm has helped support the growth of businesses such as: Airbnb, Deliveroo, Guild, Gusto, Hubspot, Illumio, Lemonade, Livongo, Oscar, Samsara, Snap, Stripe, and Warby Parker.